Library

Growth Hormone

Ipamorelin

Nearly always taken alongside CJC-1295 to raise the body's own growth hormone. The appeal is that it's 'cleaner' than older versions — less likely to spike appetite or other hormones. Human trials for this exact use are still thin, though.

Selective GH , almost always paired with CJC-1295.

How well studied

Tier Guide: A = Well studied, B = Some good studies, C = Early evidence & D = Barely studied

BHow well studiedSome good studies

Tested in people, but in smaller or fewer studies. A decent picture, just less certain.

How it works

Targets one specific hormone switch to trigger growth hormone release, leaving the appetite and stress-hormone switches alone — unlike older versions.

Selectively stimulates the to trigger GH release, without meaningfully raising cortisol or appetite.

Reported benefits

  • Raises GH/IGF-1 with a more selective profile than older secretagogues
  • Supports recovery and sleep quality as part of a GH-axis stack

Who it's typically used for

Training recovery, sleep quality — typically paired with CJC-1295

Timeline to results

Sleep/recovery changes reported within 2-4 weeks; body composition changes 8-12+ weeks

Dosage

No established human dose

No established self-administration dose — limited controlled human trials for this specific use.

Side effects

  • Injection site reactionsreported
  • Headachereported
  • Elevated IGF-1 — theoretical hormone-sensitive tissue concernmonitoring-relevant, unresolved

Getting it in the UK

Getting it in the UKPrescribable, but not approved for this

Still legal for a doctor to prescribe, but it hasn't been officially approved for this specific use. Uncommon, and comes down to a specialist's own judgement.

MHRA: the UK government body that checks a medicine is safe and actually works before doctors are allowed to prescribe it.

Content freshness

Last reviewed
11 Aug 2026
Regulatory status last checked
11 Aug 2026